

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2291)

VOLUNTARY ANNOUNCEMENT PROPOSED H SHARE REPURCHASE PLAN

This announcement is made by LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the “**Company**”) on a voluntary basis.

The chairman of the board (the “**Board**”) of directors (the “**Directors**”) of the Company has proposed to the Board to adopt a plan (the “**Proposed H Share Repurchase Plan**”) for the Company to, from time to time, repurchase the H shares of the Company (the “**H Shares**”) on the open market subject to market conditions and pursuant to a general mandate to repurchase H Shares (the “**Proposed Repurchase Mandate**”) to be approved by the shareholders of the Company (the “**Shareholders**”) at general meeting.

It is currently expected that under the Proposed H Share Repurchase Plan, the Company will utilize not more than RMB100 million to repurchase up to 5.5 million H Shares on the open market.

For the avoidance of doubt, the implementation of the Proposed H Share Repurchase Plan is subject to (i) approval of the Board; and (ii) approval of the Proposed Repurchase Mandate by the Shareholders at the upcoming annual general meeting of the Company to be held on May 22, 2026. The timing, price and amount of repurchases of H Shares will be determined based upon market conditions and other factors. Under the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange, the actual purchase price for each H Share repurchase shall not be higher by 5% or more over the average closing market price of the H Shares for the five trading days immediately preceding each such repurchase. The Company will finance the Proposed H Share Repurchase Plan from its existing available cash.

The Company considers that (i) the Proposed H Share Repurchase Plan reflects the confidence in the long-term growth and market performance of the Company; (ii) the Proposed H Share Repurchase Plan will be beneficial to the Company and create value to the Shareholders, and thus the Proposed H Share Repurchase Plan is in the best interest of the Company and the Shareholders as a whole; and (iii) the current financial resources of the Company enables it to implement the Proposed H Share Repurchase Plan while maintaining a solid financial position.

The implementation of the Proposed H Share Repurchase Plan will be subject to compliance with the Proposed Repurchase Mandate, applicable provisions of the Company's articles of association, the applicable provisions of the Listing Rules (including but not limited to Rule 10.06), The Codes on Takeovers and Mergers and Share Buy-backs (the "Takeovers Code") and other applicable laws of the People's Republic of China.

The Company is not expected to implement the Proposed H Share Repurchase Plan to the extent resulting in the number of H Shares in the hands of the public falling below the prescribed minimum percentage required by the Stock Exchange or give rise to an obligation to make a general offer to the Shareholders under Rules 26 and 32 of the Takeovers Code.

Shareholders and potential investors of the Company should note that the implementation of the Proposed H Share Repurchase Plan by the Company will be subject to market conditions and fulfillment of the abovementioned conditions. There is no assurance as to the timing, quantity or price of any H Share repurchase or whether the Company will make any repurchase at all. Shareholders and potential investors of the Company should therefore exercise caution when dealing in the securities of the Company.

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
April 1, 2026

As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*